0000000000008149

AUTHOR

Juan L. Iovanna

showing 30 related works from this author

NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance

2016

AbstractSorafenib, an oral multikinase inhibitor, is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC). However, its benefits are modest, and as its mechanisms of action remain elusive, a better understanding of its anticancer effects is needed. Based on our previous study results, we investigated here the implication of the nuclear protein 1 (NUPR1) in HCC and its role in sorafenib treatment. NUPR1 is a stress-inducible protein that is overexpressed in various malignancies, but its role in HCC is not yet fully understood. We found that NUPR1 expression was significantly higher in primary human HCC samples than in the normal liver. Knockdown of NUPR1 signi…

0301 basic medicineMaleCancer ResearchHepatocellular carcinomaCore Binding Factor Alpha 1 Subunit0302 clinical medicineCell MovementBasic Helix-Loop-Helix Transcription FactorsMolecular Targeted TherapyRNA Small InterferingRegulation of gene expressionAged 80 and overGene knockdownRELBLiver NeoplasmsMiddle AgedSorafenib3. Good healthNeoplasm ProteinsSorafenib.Gene Expression Regulation Neoplastic030220 oncology & carcinogenesisGene Knockdown TechniquesOriginal ArticleFemalemedicine.drugSorafenibNiacinamideCarcinoma HepatocellularRUNX2 GeneCell SurvivalIER3ImmunologyDown-RegulationBiology03 medical and health sciencesCellular and Molecular NeuroscienceYoung AdultmedicineGene silencingHumansNeoplasm InvasivenessGene SilencingneoplasmsAgedCell ProliferationCell growthGene Expression ProfilingPhenylurea CompoundsTranscription Factor RelBComputational BiologyMembrane ProteinsCell BiologyNuclear protein-1digestive system diseases030104 developmental biologyDrug Resistance NeoplasmCancer researchApoptosis Regulatory ProteinsTranscriptomeCell Death & Disease
researchProduct

Nupr1-Aurora Kinase A Pathway Provides Protection against Metabolic Stress-Mediated Autophagic-Associated Cell Death

2012

Abstract Purpose: The limited supply of oxygen and nutrients is thought to result in rigorous selection of cells that will eventually form the tumor. Experimental Design: Nupr1 expression pattern was analyzed in human tissue microarray (TMA) and correlated with survival time of the patient. Microarray analysis was conducted on MiaPaCa2 cells subjected to metabolic stress in Nupr1-silenced conditions. DNA repair and cell cycle–associated gene expression was confirmed by real-time quantitative PCR (qRT-PCR). Nupr1 and AURKA protective role were analyzed using RNA interference (RNAi) silencing or overexpression. DNA damage and autophagy were analyzed by Western blot analysis and immunofluoresc…

Cancer ResearchProgrammed cell deathCell SurvivalDNA damageDNA repairAdenocarcinomaProtein Serine-Threonine KinasesBiologyAurora KinasesStress PhysiologicalCell Line TumorAutophagyBasic Helix-Loop-Helix Transcription FactorsHumansGene silencingAurora Kinase ARegulation of gene expressionGene knockdownMicroarray analysis techniquesAURKA GeneMolecular biologyCell HypoxiaNeoplasm ProteinsCell biologyGene Expression Regulation NeoplasticGlucoseOncologyRNA InterferenceCarcinoma Pancreatic DuctalClinical Cancer Research
researchProduct

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoin…

2021

Gastrointestinal stromal tumors (GISTs) represent 1% of all primary gastrointestinal tumors. Immune surveillance is often overcome by cancer cells due to the activation of immunoregulatory molecules such as programmed death protein (PD-1) and its ligand PD-L1, and butyrophilin sub-family 3A/CD277 receptors (BTN3A). Because several studies demonstrated that tumor PD-1 and PD-L1 expression may have a prominent prognostic function, this investigation aimed to discover if soluble forms of these molecules may be useful in predicting survival of metastatic GIST (mGIST) patients. Through specific ad hoc developed ELISA assays not yet available on the market, the circulating PD-1, PD-L1, BTN3A1, an…

PD-L10301 basic medicineCancer ResearchStromal cellSettore MED/06 - Oncologia MedicaArticle03 medical and health sciencesExon0302 clinical medicineImmune systemButyrophilinPD-L1PD-1Medicineprognostic biomarkerReceptorRC254-282butyrophilinsbiologyGiSTbusiness.industrycirculating immune checkpointsNeoplasms. Tumors. Oncology. Including cancer and carcinogensBTN3A1Antitumor immune response BTN3A1 Butyrophilins Circulating immune checkpoints GIST PD‐1 PD‐L1 Prognostic biomarkerantitumor immune response030104 developmental biologyOncology030220 oncology & carcinogenesisCancer cellCancer researchbiology.proteinbusinessGISTCancers
researchProduct

Cancer Clonal Evolution and Intra-tumor Heterogeneity

2017

Despite recent advances in understanding cancer onset mechanisms and development of new therapeutic approaches, however, the resistance of tumor cells to different therapies represents the main obstacle to the successful treatment, resulting in poor prognosis and tumor recurrence. Currently, understanding the causes underlying this resistance is the main objective of oncology research in recent years. Tumors are not uniform diseases but heterogeneous entities consisting of cell populations called clones, with different genetic and molecular characteristics. Indeed, most of cancers shows usually a single clonal origin at the early stages of the disease, but, in advanced stages, tumors may in…

Mechanism (biology)Cancer stem cellMelanomamedicineCancer researchCancerGenetic variabilityDiseaseDrug resistanceBiologymedicine.diseaseSomatic evolution in cancer
researchProduct

Tumor Biology and Natural History

2021

Tumors are not uniform diseases but heterogeneous entities consisting of cell populations called cell clones, with different genetic and molecular features. The ability of a tumor to evolve and fit to host microenvironment, by developing often resistance mechanisms to the anticancer therapies, is dependent on this biological variability. In fact, the variability observed within individual tumors, known as intra-tumor heterogeneity, represents the crucial step in cancer clonal evolution process, by promoting and driving a genetic mechanism able to select the fittest cell clones. A single clonal origin is usually shown by most of tumors at the early stages of the disease, whereas advanced-sta…

Natural historymedicine.anatomical_structureMechanism (biology)CellmedicineCancerDiseaseGenetic variabilityComputational biologyBiologymedicine.diseaseSomatic evolution in cancerMetastasis
researchProduct

NUPR1 works against the metabolic stress-induced autophagy-associated cell death in pancreatic cancer cells.

2013

The incidence of pancreatic adenocarcinoma is increasing with more than 43,000 predicted new cases in the US and 65,000 in Europe this year. Pancreatic cancer patients have a short life expectancy with less than 3–4% 5-y survival, which results in an equivalent incidence and mortality rate. One of the major challenges in pancreatic cancer is the identification of pharmacological approaches that overcome the resistance of this cancer to therapy. Intensive research in the past decades has led to the classification of pancreatic cancers and the identification of the driver key genetic events. Despite the advances in understanding the molecular mechanisms responsible for pancreatic cancer patho…

Oncologymedicine.medical_specialtyCell SurvivalDrug resistanceDiseaseBiologyProtein Serine-Threonine KinasesModels BiologicalAurora KinasesStress PhysiologicalPancreatic cancerInternal medicineCarcinomamedicineAutophagyBasic Helix-Loop-Helix Transcription FactorsHumansMolecular BiologyCell DeathMechanism (biology)Mortality rateCancerCell Biologymedicine.diseaseAutophagic PunctumNeoplasm ProteinsEndocrinologyDrug Resistance NeoplasmAdenocarcinomaCarcinoma Pancreatic DuctalAutophagy
researchProduct

Targeting NUPR1 with the Small Compound ZZW-115 Is an Efficient Strategy to Treat Hepatocellular Carcinoma

2020

International audience; HCC is a highly lethal malignancy with Sorafenib as the only molecularly targeted drug. The multifunctional stress-associated protein, NUPR1, plays an essential role in controlling cell growth, migration, invasion and Sorafenib resistance in HCC. We report here that NUPR1 expression is absent in healthy liver and it is progressively upregulated in HCC premalignant lesions such as hepatitis and cirrhosis with a maximum expression in HCC samples, highlighting that NUPR1 is a potential drug target for HCC. We therefore assessed in this work, ZZW-115, a strong inhibitor of NUPR1, as a promising candidate for the treatment of HCC. We validated its extraordinary antitumor …

ZZW-1150301 basic medicineSorafenibCancer ResearchProgrammed cell deathNecrosisApoptosis InhibitorNecroptosis[SDV]Life Sciences [q-bio]Apoptosis[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineHepatocellular Carcinoma (HCC)medicineneoplasmsComputingMilieux_MISCELLANEOUSApoptosis HCC Necroptosis NUPR1 ZZW-115Cell growthbusiness.industrymedicine.diseasedigestive system diseases3. Good health030104 developmental biologyOncologyApoptosis030220 oncology & carcinogenesisHepatocellular carcinomaNecroptosisCancer researchmedicine.symptombusinessNUPR1medicine.drug
researchProduct

Cancer of Exocrine Pancreas

2021

Pancreatic adenocarcinoma represents today a real challenge for oncologists all around the world: it is the 11th most common cancer worldwide, and the 7th deadliest, with a steadily increasing number of new cases every year. Many risk factors, both environmental and genetic, have been identified, the most important of which are excessive body weight, diabetes, and smoking; also, new diagnostic techniques, such as spiral TC, MRCP, and EUS, have improved the ability to diagnose this disease at an early stage. Nevertheless, pancreatic cancer is a silent disease, with few or no symptoms and signs until late stages: the vast majority of patients are inoperable at the time of diagnosis, with eith…

Oncologymedicine.medical_specialtybusiness.industryFOLFIRINOXmedicine.medical_treatmentCancerDiseasemedicine.diseaseInternal medicinePancreatic cancerPancreatectomyMedicineAdenocarcinomaCA19-9Stage (cooking)business
researchProduct

Response to "Is the Reg3α (HIP/PAP) Protein Really an Obesogenic Factor?"

2015

Peer Reviewed

Male0301 basic medicinePhysiologyClinical BiochemistryeducationMEDLINEPancreatitis-Associated ProteinsBiologyClinical biochemistry03 medical and health sciences0302 clinical medicineAnimalsHumansObesityPancreatitis-Associated ProteinsAnimalProteinMedicine (all)ProteinsCell BiologyBlood coagulation factorsBlood Coagulation Factors030104 developmental biology030220 oncology & carcinogenesisProteins metabolismImmunologyFemaleBlood Coagulation FactorHuman
researchProduct

Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor ce…

2010

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Celecoxib (Celebrex®) exhibits antitumor effects in human HCC cells, and its mechanism of action is mediated either by its ability to inhibit cyclooxygenase 2 (COX-2) or by a number of various other COX-2 independent effects. Proteasome inhibitors (PIs) can exert cell growth inhibitory and apoptotic effects in different tumor cell types, including HCC cells. The present study examined the interaction between celecoxib and the PI MG132 in two human liver tumor cell lines HepG2 and HA22T/VGH. Our data showed that each inhibitor reduced proliferation and induced apoptosis in a dose-dependen…

MG132TRB3Programmed cell deathLeupeptinsBlotting WesternApoptosisUPRPharmacologyCysteine Proteinase Inhibitorschemistry.chemical_compoundMG132medicineHumansViability assayHCCMolecular BiologyCell ProliferationSettore MED/12 - GastroenterologiaGene knockdownSulfonamidesbiologyCyclooxygenase 2 InhibitorsCell growthReverse Transcriptase Polymerase Chain ReactionDrug SynergismCell BiologyHep G2 CellsCOX-2ER stress responseFlow CytometryapoptosiproteasomechemistryApoptosisCelecoxibSettore BIO/14 - Farmacologiabiology.proteinProteasome inhibitorPyrazolesCyclooxygenaseDevelopmental Biologymedicine.drug
researchProduct

Expression of HIP/PAP mRNA in Human Hepatoma Cell Lines

2002

The present study attempts to shed more light on the role of hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) in hepatoma cells. We initially examined, by reverse transcription-polymerase chain reaction (RT-PCR), the HIP/PAP transcripts present in human hepatoma cell lines of different origins and with different grades of differentiation and genetic profiles. We also used DNA sequencing analysis to investigate the structure of the HIP/PAP gene. Further investigation is necessary to define the role of HIP/PAP during the development of human hepatocellular carcinoma and to ascertain whether the use of different transcripts is helpful in regulating HIP/PAP expression …

Pathologymedicine.medical_specialtyCarcinoma HepatocellularSettore MED/09 - Medicina InternaPancreatitis-Associated ProteinscarcinomaGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of ScienceAntigenAntigens NeoplasmHIP/PAPBiomarkers TumorTumor Cells CulturedmedicineCarcinomaHumansNeoplasmLectins C-TypeRNA MessengerPancreatitis-Associated ProteinsN-Glycosyl HydrolasesGenePlant ProteinsMessenger RNAbusiness.industryGeneral NeuroscienceLiver NeoplasmsAcute-phase proteinpancreatitihepatomamedicine.diseasePancreatitisHepatocellular carcinomaRibosome Inactivating Proteins Type 1Cancer researchproteinbusinessAcute-Phase ProteinsAnnals of the New York Academy of Sciences
researchProduct

Response to the Letter to the editor regarding “Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carc…

2021

therapyCancer ResearchCarcinoma HepatocellularLetter to the editorbusiness.industryLiver Neoplasmshepatocellular carcinomamedicine.diseaseNeoplasm ProteinsGene Expression Regulation NeoplasticOncologyHepatocellular carcinomaCancer researchHumansMedicineStress ProteinsbusinessCancer Letters
researchProduct

Autophagy

2012

Klionsky, Daniel J. et al.

autophagy assays[SDV]Life Sciences [q-bio]AutolysosomeAutophagosome maturationautophagosomeBioinformaticsstressChaperone-mediated autophagyModelsLC3MESH: Animalsguidelinesautolysosome autophagosome flux LC3 lysosome phagophore stress vacuoleSettore BIO/06 - Anatomia Comparata E CitologiaComputingMilieux_MISCELLANEOUSSettore BIO/17Autophagy databaseautolysosome3. Good healthddc:540lysosomeEnergy and redox metabolism Mitochondrial medicine [NCMLS 4]methods [Biological Assay]Biological AssaySettore BIO/17 - ISTOLOGIANeuroniMAP1LC3BHumanautophagygenetics [Autophagy]AutofagiaMESH: Autophagy*/genetics[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAutofagia; Neuroni; istologiaBiologyModels BiologicalLC3; autolysosome; autophagosome; flux; lysosome; phagophore; stress; vacuoleddc:570AutophagyAnimalsHumansAutophagy-Related Protein 7[SDV.BC] Life Sciences [q-bio]/Cellular BiologyBiological Assay/methodsMolecular BiologyBiologyAutophagy; guidelines; autophagy assaysistologiaphagophoreMESH: HumansAnimals; Biological Assay; Humans; Models Biological; AutophagyvacuoleAnimal[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyMESH: Models BiologicalPathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1]Cell BiologyBiologicalAutophagy/geneticsfluxAutophagosome membraneAutophagy Protein 5Human medicineMESH: Biological Assay/methods*Neuroscienceautolysosome; autophagosome; flux; LC3; lysosome; phagophore; stress; vacuoleAutophagy
researchProduct

Clinical evaluation of pancreatitis-associated protein as a serum marker of hepatocellular carcinoma: Comparison with α-fetoprotein

1998

This study evaluated the significance of serum pancreatitis-associated protein (PAP) assay, as a marker of hepatocellular carcinoma (HCC), in comparison and combined with α-fetoprotein (AFP) assay. Sixty-five patients with HCC, 59 with liver cirrhosis (LC) and 68 asymptomatic controls (C) were studied. PAP and AFP values significantly increased from C to LC and HCC group (p < 0.0001). The area under receiver-operating characteristic (ROC) curve for the two markers was not statistically different. At 100% specificity, ROC analysis gave a cut-off level for AFP of 166 IU/l with 40% sensitivity, and a cut-off level of 240 µg/l for PAP with 23% sensitivity. Diagnostic accuracy of combined AFP…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyCirrhosisCarcinoma HepatocellularPancreatitis-Associated ProteinsAsymptomaticSensitivity and SpecificityAntigens NeoplasmBiomarkers TumorMedicineHumansLectins C-TypeneoplasmsTumor markerAgedbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasedigestive system diseasesLogistic ModelsOncologyHepatocellular carcinomaPancreatitisFemalealpha-Fetoproteinsmedicine.symptombusinessClinical evaluationSerum markersAcute-Phase Proteins
researchProduct

Germline copy number variation in theYTHDC2gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcin…

2014

Abstract: Objective: The vast majority of pancreatic cancers occurs sporadically. The discovery of frequent variations in germline gene copy number can significantly influence the expression levels of genes that predispose to pancreatic adenocarcinoma. We prospectively investigated whether patients with sporadic pancreatic adenocarcinoma share specific gene copy number variations (CNVs) in their germline DNA. Patients and methods: DNA samples were analyzed from peripheral leukocytes from 72 patients with a diagnosis of sporadic pancreatic adenocarcinoma and from 60 controls using Affymetrix 500K array set. Multiplex ligation-dependent probe amplification (MLPA) assay was performed using a s…

Malecopy number variations germline alteration pancreatic cancer susceptibility YTHDC2 geneDNA Copy Number VariationsSettore MED/06 - Oncologia MedicaClinical BiochemistryAdenocarcinomaBiologyGermlinePancreatic cancerDrug DiscoverymedicineHumansGenetic Predisposition to DiseaseMultiplexProspective StudiesMultiplex ligation-dependent probe amplificationCopy-number variationAlleleGeneGerm-Line MutationAgedAdenosine TriphosphatasesAged 80 and overPharmacologyPharmacology. TherapyDNA HelicasesMiddle Agedmedicine.diseaseMolecular biologyPancreatic NeoplasmsCase-Control StudiesMolecular MedicineAdenocarcinomaFemaleMultiplex Polymerase Chain ReactionRNA HelicasesExpert Opinion on Therapeutic Targets
researchProduct

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastat…

2020

Introduction of checkpoint inhibitors resulted in durable responses and improvements in overall survival in advanced RCC patients, but the treatment efficacy is widely variable, and a considerable number of patients are resistant to PD-1/PD-L1 inhibition. This variability of clinical response makes necessary the discovery of predictive biomarkers for patient selection. Previous findings showed that the epigenetic modifications, including an extensive microRNA-mediated regulation of tumor suppressor genes, are key features of RCC. Based on this biological background, we hypothesized that a miRNA expression profile directly identified in the peripheral lymphocytes of the patients before and a…

PD-L10301 basic medicinerenal cell carcinomaCancer Researchmedicine.medical_treatmentLymphocytelcsh:RC254-282Articlepredictive biomarkers03 medical and health sciences0302 clinical medicineRenal cell carcinomaPD-L1PD-1microRNAmedicineEpigeneticsmiRNAmicroRNAbiologybusiness.industrysoluble immune checkpointsImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePredictive biomarker030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchbiology.proteinNivolumabbusinessReprogrammingCancers
researchProduct

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

2016

Seuls les 100 premiers auteurs dont les auteurs INRA ont été entrés dans la notice. La liste complète des auteurs et de leurs affiliations est accessible sur la publication.; International audience; In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues…

[SDV]Life Sciences [q-bio]autophagosomeReview Articleddc:616.07stressstreLC3MESH: AnimalsSettore MED/49 - Scienze Tecniche Dietetiche ApplicateSettore BIO/06 - Anatomia Comparata E Citologiachaperone-mediated autophagyComputingMilieux_MISCELLANEOUSSettore BIO/11Pharmacology. TherapySettore BIO/13standards [Biological Assay]autolysosomeMESH: Autophagy*/physiologylysosomemethods [Biological Assay]Biological AssaySettore BIO/17 - ISTOLOGIAErratumHumanBiochemistry & Molecular BiologySettore BIO/06physiology [Autophagy]Chaperonemediated autophagy[SDV.BC]Life Sciences [q-bio]/Cellular BiologyNOautophagy guidelines molecular biology ultrastructureautolysosome; autophagosome; chaperone-mediated autophagy; flux; LC3; lysosome; macroautophagy; phagophore; stress; vacuoleMESH: Biological Assay/methodsMESH: Computer Simulationddc:570Autolysosome Autophagosome Chaperonemediated autophagy Flux LC3 Lysosome Macroautophagy Phagophore Stress VacuoleAutophagyAnimalsHumansComputer SimulationSettore BIO/10ddc:612BiologyphagophoreMESH: HumansvacuoleAnimalLC3; autolysosome; autophagosome; chaperone-mediated autophagy; flux; lysosome; macroautophagy; phagophore; stress; vacuole; Animals; Biological Assay; Computer Simulation; Humans; Autophagy0601 Biochemistry And Cell BiologyfluxmacroautophagyMESH: Biological Assay/standards*Human medicineLC3; autolysosome; autophagosome; chaperone-mediated autophagy; flux; lysosome; macroautophagy; phagophore; stress; vacuole
researchProduct

Cloning and Expression of the mRNA of Human Galectin-4, an S-type Lectin Down-Regulated in Colorectal Cancer

1997

We are interested in the characterization of genes whose expressions in the colon are modified during colorectal carcinogenesis. Our approach was to establish the phenotype of a colon tumor by partial sequencing of a large number of transcripts, then to select mRNAs of potential interest by differential screening with complex probes from normal or cancerous colon. In this paper, we report the cloning and sequencing of a mRNA strongly underexpressed in colorectal cancer. It corresponded to a protein comprising 323 amino acids, that appeared to be human galectin-4 on the basis of 76% and 79% amino acid identity to the rat and pig counterparts, respectively. Tissue distribution analysis showed…

Genetic MarkersDNA ComplementaryColorectal cancerGalectin 4Molecular Sequence DataDown-RegulationRectumBiologyBiochemistryLectinsBiomarkers TumorTumor Cells CulturedmedicineHumansAmino Acid SequenceRNA MessengerRNA NeoplasmCloning MolecularGeneCloningExpressed sequence tagMessenger RNABase SequenceSequence Homology Amino AcidDNA Neoplasmmedicine.diseaseMolecular biologyPhenotypedigestive system diseasesGene Expression Regulation NeoplasticHemagglutininsmedicine.anatomical_structureCell cultureColorectal NeoplasmsEuropean Journal of Biochemistry
researchProduct

NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response

2021

AbstractBackground and AimsNon-alcoholic fatty liver disease and related hepatic syndromes affect up to one third of the adult population. The molecular mechanisms underlying NAFL etiology remain elusive. Nuclear Protein 1 (NUPR1) expression increases upon cell injury in all organs and recently we report its active participation in the activation of the Unfolded Protein Response (UPR). The UPR typically maintains protein homeostasis, but downstream mediators of the pathway regulate metabolic functions, including lipid metabolism. NUPR1 and UPR increase have been reported in obesity and liver pathologies and the goal of this study was to investigate the roles of NUPR1 in this context.Methods…

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaPPAR-a signalling UPRPeroxisome proliferator-activated receptorContext (language use)UPRDiet High-FatBiochemistry03 medical and health sciencesLiver diseaseMice0302 clinical medicineInternal medicineCell Line TumorGeneticsmedicineBasic Helix-Loop-Helix Transcription FactorsAnimalsHomeostasisHumansMolecular Biologychemistry.chemical_classificationbusiness.industryEndoplasmic reticulumFatty liverNASHLipid metabolismlipotoxicitymedicine.diseaseEndoplasmic Reticulum StressLipid MetabolismNeoplasm Proteins030104 developmental biologyEndocrinologychemistryLipotoxicityLiverNAFLKnockout mouseUnfolded protein responseUnfolded Protein ResponsePPAR-a signallingSteatosisSteatohepatitisbusiness030217 neurology & neurosurgeryNUPR1Biotechnology
researchProduct

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a…

2020

Despite a proportion of renal cancer patients can experiment marked and durable responses to immune-checkpoint inhibitors, the treatment efficacy is widely variable and identifying the patient who will benefit from immunotherapy remains an issue. We performed a prospective study to investigate if soluble forms of the immune-checkpoints PD-1 (sPD-1), PD-L1 (sPD-L1), pan-BTN3As, BTN3A1, and BTN2A1, could be candidate to predict the response to immune-checkpoint blockade therapy. We evaluated the plasma levels in a learning cohort of metastatic clear cell renal carcinoma (mccRCC) patients treated with the anti-PD-1 agent nivolumab by ad hoc developed ELISA’s. Using specific cut-offs determined…

0301 basic medicineOncologySettore MED/06 - Oncologia MedicaProgrammed Cell Death 1 ReceptorB7-H1 Antigen0302 clinical medicineRenal cell carcinomaPD-1Immunology and AllergyProspective Studiespredictive biomarkerRC254-282ComputingMilieux_MISCELLANEOUSOriginal ResearchbiologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensfood and beveragesBTN3A1PrognosisTreatment efficacyKidney Neoplasms3. Good healthNivolumabOncology030220 oncology & carcinogenesisBiomarker (medicine)[SDV.IMM]Life Sciences [q-bio]/Immunologysoluble immune-checkpointsNivolumabResearch ArticlePD-L1medicine.medical_specialtyrenal cell carcinomabutyrophilinImmunology03 medical and health sciencesAntigens CDInternal medicinePD-L1mental disordersmedicineHumansIn patientCarcinoma Renal Cellbutyrophilinsbusiness.industryCancercirculating immune checkpointsPlasma levelsRC581-607medicine.diseasecirculating immune checkpoint030104 developmental biologyBTN2A1immunotherapy responsebiology.proteinImmunologic diseases. Allergybusiness
researchProduct

Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?

2019

International audience; In recent years, multiple strategies for eliciting anti-tumor immunity have been developed in different clinical studies. Currently, immunotherapy was clinically validated as effective treatment option for many tumors such as melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Some surface receptors of immune cells, called immune checkpoint receptors, may inhibit activity of proinflammatory lymphocytes, following binding with specific ligands. Cancer cells exploit these mechanisms to inactivate tumor-infiltrating lymphocytes (TILs) to escape from immunosurveillance. Among the different tumor-infiltrating immune cell populations, including leu…

PD-L10301 basic medicinePrognosiSettore MED/06 - Oncologia Medica[SDV]Life Sciences [q-bio]medicine.medical_treatmentImmunologyPredictive significance[SDV.CAN]Life Sciences [q-bio]/Cancerchemical and pharmacologic phenomenaBiology03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemNeoplasmsImmune suppressionPD-1Biomarkers TumormedicineAnimalsHumansTumor microenvironmentTumor-infiltrating lymphocytesMelanomaImmunotherapyPrognosismedicine.diseaseImmune checkpoint3. Good healthImmunosurveillance030104 developmental biologyTumor microenvironment030220 oncology & carcinogenesisCancer cellTumor immunologyCancer researchImmunotherapy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyTumor-infiltrating lymphocytes (TILs)Cellular Immunology
researchProduct

The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma

2021

The multikinase inhibitor sorafenib was the first drug approved by the FDA for treating patients with advanced hepatocellular carcinoma (HCC). However, sorafenib resistance remains a major challenge for improving the effectiveness of HCC treatment. Previously, we identified several genes modulated after sorafenib treatment of human HCC cells, including the stress-inducible nuclear protein 1 (NUPR1) gene. Multiple studies have shown that NUPR1 regulates autophagy, apoptosis, and chemoresistance. Here, we demonstrate that treatment of HCC cells with sorafenib resulted in the activation of autophagic flux. NUPR1 knock-down (KD) in HCC cells was associated with increased p62 expression, suggest…

SorafenibCancer ResearchCarcinoma HepatocellularSettore MED/09 - Medicina InternaHepatocellular carcinomap73Mice NudeApoptosisSettore BIO/11 - Biologia MolecolareMiceNSC5594In vivoPumaBasic Helix-Loop-Helix Transcription FactorsmedicineAutophagyNSC5994AnimalsHumansGene silencingneoplasmsbiologyActivator (genetics)business.industryLiver NeoplasmsAutophagyApoptosiTumor Protein p73Hep G2 CellsSorafenibbiology.organism_classificationmedicine.diseasedigestive system diseasesNeoplasm ProteinsOncologyDrug Resistance NeoplasmApoptosisHepatocellular carcinomaCancer researchFemalebusinessNUPR1medicine.drug
researchProduct

Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.

2007

Pancreatic cancer is a disease with an extremely poor prognosis. Tumor protein 53-induced nuclear protein 1 ( TP53INP1 ) is a proapoptotic stress-induced p53 target gene. In this article, we show by immunohistochemical analysis that TP53INP1 expression is dramatically reduced in pancreatic ductal adenocarcinoma (PDAC) and this decrease occurs early during pancreatic cancer development. TP53INP1 reexpression in the pancreatic cancer-derived cell line MiaPaCa2 strongly reduced its capacity to form s.c., i.p., and intrapancreatic tumors in nude mice. This anti-tumoral capacity is, at least in part, due to the induction of caspase 3-mediated apoptosis. In addition, TP53INP1 −/− mouse embryonic…

Settore MED/06 - Oncologia MedicaTransplantation HeterologousGene ExpressionMice NudeMicePancreatic tumorPancreatic cancerCell Line TumormicroRNAGene expressionmedicineAnimalsHumansRNA NeoplasmNuclear proteinCaspaseHeat-Shock ProteinsMice KnockoutMultidisciplinarybiologyBase Sequenceapoptosis pancreatic cancer ponasterone A tumor suppressor micro RNANuclear ProteinsBiological Sciencesmedicine.diseaseTransplantationPancreatic NeoplasmsMicroRNAsCell Transformation NeoplasticApoptosisCancer researchbiology.proteinTumor Suppressor Protein p53Carrier ProteinsNeoplasm TransplantationCarcinoma Pancreatic DuctalProceedings of the National Academy of Sciences of the United States of America
researchProduct

738P Soluble PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTN2A1 as predictive biomarkers of nivolumab response in patients with metastatic clear cell renal c…

2020

Oncologymedicine.medical_specialtybiologybusiness.industryHematologyOncologyInternal medicinePD-L1Clear Cell Renal Carcinomamedicinebiology.proteinIn patientNivolumabbusinessPredictive biomarkerAnnals of Oncology
researchProduct

PAP/HIP Protein Is an Obesogenic Factor

2013

In this article we report the obesogenic role of the acute phase protein PAP/HIP. We found that the transgenic TgPAP/HIP mice develop spontaneous obesity under standard nutritional conditions, with high levels of glucose, leptin, and LDL and low levels of triglycerides and HDL in blood. Accordingly, PAP/HIP-deficient mice are skinny under standard nutritional conditions. We also found that expression of PAP/HIP is induced in intestinal epithelial cells in response to gavage with olive oil and this induction is AG490 sensitive. We demonstrated that incubation of 3T3-L1 preadipocytes with a low concentration as 1 ng/ml of recombinant PAP/HIP results in accelerated BrdU incorporation in vitro.…

medicine.medical_specialtyPhysiologybusiness.industryLeptinMEK inhibitorTransgeneClinical BiochemistryAcute-phase proteinAdipose tissueCell Biologymedicine.diseaseObesityIn vitroEndocrinologyInternal medicinemedicinePancreatitis-Associated ProteinsbusinessJournal of Cellular Physiology
researchProduct

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients?

2019

e14035 Background: The immune response to melanoma has been shown to be locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk (infiltrating the entire base of the invasive tumor), non-brisk (infiltrating only focally) and absent. Several studies showed that greater presence of TILs, especially brisk, in primary melanoma is associated with a better prognosis and a higher survival rate. Since recent studies revealed an association between PD-1/PD-L1 expression levels and tumor response, the aim of our study was to investigate the correlation between plasma PD-1 and presence/absence/class of TILs in metastatic melanoma patients. Methods: The plasm…

Cancer ResearchMetastatic melanomaTumor-infiltrating lymphocytesbusiness.industryMelanomahemic and immune systemschemical and pharmacologic phenomenamedicine.disease03 medical and health sciences0302 clinical medicineImmune systemOncology030220 oncology & carcinogenesisCancer researchmedicineplasma PD-1 tumor-infiltrating lymphocytes metastatic melanomabusiness030215 immunologyJournal of Clinical Oncology
researchProduct

Erratum

2016

Author(s): Klionsky, DJ; Abdelmohsen, K; Abe, A; Abedin, MJ; Abeliovich, H; Arozena, AA; Adachi, H; Adams, CM; Adams, PD; Adeli, K; Adhihetty, PJ; Adler, SG; Agam, G; Agarwal, R; Aghi, MK; Agnello, M; Agostinis, P; Aguilar, PV; Aguirre-Ghiso, J; Airoldi, EM; Ait-Si-Ali, S; Akematsu, T; Akporiaye, ET; Al-Rubeai, M; Albaiceta, GM; Albanese, C; Albani, D; Albert, ML; Aldudo, J; Algul, H; Alirezaei, M; Alloza, I; Almasan, A; Almonte-Beceril, M; Alnemri, ES; Alonso, C; Altan-Bonnet, N; Altieri, DC; Alvarez, S; Alvarez-Erviti, L; Alves, S; Amadoro, G; Amano, A; Amantini, C; Ambrosio, S; Amelio, I; Amer, AO; Amessou, M; Amon, A; An, Z; Anania, FA; Andersen, SU; Andley, UP; Andreadi, CK; Andrieu-Ab…

0301 basic medicineSettore BIO/06biologyCell Biology[SDV.BC]Life Sciences [q-bio]/Cellular Biologybiology.organism_classificationCell biologyInterpretation (model theory)03 medical and health sciencesArama030104 developmental biologyMolecular BiologyHumanitiesComputingMilieux_MISCELLANEOUS
researchProduct

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

2019

Background: The immune response in melanoma patients is locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk, nonbrisk, and absent. Several studies have shown that a greater presence of TILs, especially brisk, in primary melanoma is associated with a better prognosis and higher survival rate. Patients and Methods: We investigated by enzyme-linked immunosorbent assay (ELISA) the correlation between PD-1 levels in plasma and the presence/absence of TILs in 28 patients with metastatic melanoma. Results: Low plasma PD-1 levels were correlated with brisk TILs in primary melanoma, whereas intermediate values correlated with the nonbrisk TILs, and hig…

Metastatic melanoma[SDV]Life Sciences [q-bio]plasma PD-1chemical and pharmacologic phenomena[SDV.BC]Life Sciences [q-bio]/Cellular Biologylcsh:RC254-282immune response03 medical and health sciences0302 clinical medicineImmune systembrisk TILmelanomaMedicineIn patientOriginal Researchplasma PD-L1030304 developmental biology0303 health sciencesTumor-infiltrating lymphocytesbusiness.industryMelanomahemic and immune systemslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasebrisk TILs3. Good healthOncologytumor-infiltrating lymphocytes030220 oncology & carcinogenesisCancer researchbusinesshuman activitiesTherapeutic Advances in Medical Oncology
researchProduct

Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma

2018

In this study, our aim is to assess the role played by autophagy and its inhibition in the different PDAC cellular compartments, and its involvement in chemo-resistance using primary human pancreatic cancer-derived cells (PCC) and Cancer Associated Fibroblasts (CAF). Autophagy flux, as measured by LC3-I and -II in the presence of Chloroquine, showed a variable level in PCC and CAFs. We found no correlation between autophagy level and degree of tumor differentiation. Association of Chloroquine with gemcitabine, 5FU, oxaliplatin, irinotecan and docetaxel revealed that its effect on survival is cell- and drug-dependent in vitro and in vivo. In addition, we demonstrated that autophagy in CAFs c…

0301 basic medicineautophagyCIENCIAS MÉDICAS Y DE LA SALUDCiencias de la Salud//purl.org/becyt/ford/3.3 [https]03 medical and health sciences0302 clinical medicinepancreas cancerChloroquineMedicineCHLOROQUINEbusiness.industryAutophagygemcitabineCancerChloroquinemedicine.diseaseGemcitabineOxaliplatinOtras Ciencias de la SaludIrinotecanPANCREAS CANCER030104 developmental biologyGEMCITABINEOncologyDocetaxel030220 oncology & carcinogenesisCancer researchAdenocarcinomaAUTOPHAGY//purl.org/becyt/ford/3 [https]businessResearch Papermedicine.drugOncotarget
researchProduct

pap, reg I? andreg I? mRNAs are concomitantly up-regulated during human colorectal carcinogenesis

1999

We have established the phenotype of a colorectal tumor by partial sequencing of 2166 transcripts that were eventually arrayed on high-density filters. These filters were used for differential screening with mRNAs of colorectal cancer and normal adjacent mucosa to characterize genes whose expression is altered in colorectal carcinoma. Three genes encoding related proteins, PAP, reg Iα and reg Iβ, were over-expressed in cancer. Northern-blot analysis confirmed that their expression was very low in normal colonic epithelial cells, but elevated in 75% of tumors. Western blotting with specific antibodies to pap and reg Iα revealed in tumors a single band of the expected size (15–16 kDa), demons…

Cancer ResearchReporter genePathologymedicine.medical_specialtyCancerBiologymedicine.disease_causemedicine.diseaseMolecular biologyBlotOncologyGene expressionmedicineCarcinomaGene silencingImmunohistochemistryCarcinogenesisInternational Journal of Cancer
researchProduct